Compare peptides
Put two entries side by side — evidence, mechanism, risks, and community claims.
Tesamorelin
Clinical
FDA-approved (specific use)
Summary
FDA-approved GHRH analog for reducing excess abdominal fat in HIV-associated lipodystrophy; also discussed for visceral fat in biohacking circles.
Categories
Growth Hormone Axis, Metabolic & Body Comp
Mechanism
GHRH receptor agonist increasing endogenous GH and IGF-1, which can reduce visceral adipose tissue in indicated patients.
Half-life
~26–38 minutes (but clinical effects via GH/IGF-1 axis)
Routes
Subcutaneous injection
Legal / access
FDA-approved for a specific HIV lipodystrophy indication. Off-label and research-market versions should not be confused with the approved product.
Key risks
- Arthralgia
- Peripheral edema
- Injection-site reactions
- Elevated IGF-1
Common claims
- Targeted visceral fat reduction
- Improved metabolic profile markers
- Body-recomp edge versus older secretagogues
Select peptide B